Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease

MT Newswires Live

06/30

Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.

Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.

The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.

Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2647515485"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647515485\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647515485?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647515485","market":"sg","top_or_hot":-1,"title":"Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease","media":"MT Newswires Live","content":"<html><body><p> Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.</p><p>Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.</p><p>The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.</p><p>Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-30 21:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.</p><p>Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.</p><p>The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.</p><p>Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCYX","symbol_name":"SCYNEXIS Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647515485","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647515485","pubTimestamp":1782826132,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Scynexis  said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCYX":"SCYNEXIS Inc","BK4007":"制药","SCY":"Simplify US Small Cap PLUS Income ETF"},"translate_title":"Scynexis启动SCY-770治疗常染色体显性多囊肾病的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCYX":1,"SCY":1.5},"content_text":"Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}